Axicabtagene ciloleucel for the treatment of relapsed or refractory follicular lymphoma

Jared A. Cohen, Armin Ghobadi

Research output: Contribution to journalArticlepeer-review

Abstract

Introduction: Axicabtagene ciloleucel is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy that was recently approved for relapsed or refractory follicular lymphoma following progression on two or more lines of therapy including an anti-CD20 monoclonal antibody with an alkylating agent, providing a therapeutic breakthrough in a subset of indolent non-Hodgkin lymphoma associated with poor clinical outcomes. Areas covered: In this article, we outline the drug profile of axicabtagene ciloleucel in comparison to currently approved agents and other CAR T-cell and T-cell redirecting therapies under investigation for the treatment of relapsed or refractory follicular lymphoma. We also review the efficacy, safety, and pharmacokinetic data from the ZUMA-5 phase II trial, which forms the basis of the recent approval of axicabtagene ciloleucel. Expert opinion: Axicabtagene ciloleucel is the first cellular therapy approved for relapsed or refractory follicular lymphoma, demonstrating high rates of durable responses and a manageable toxicity profile in heavily pre-treated patients.

Original languageEnglish
Pages (from-to)903-914
Number of pages12
JournalExpert Review of Anticancer Therapy
Volume22
Issue number9
DOIs
StatePublished - 2022

Keywords

  • CAR T-cell
  • Follicular lymphoma
  • axicabtagene ciloleucel
  • bispecific antibody
  • cellular therapy
  • indolent non-Hodgkin’s lymphoma
  • treatment

Fingerprint

Dive into the research topics of 'Axicabtagene ciloleucel for the treatment of relapsed or refractory follicular lymphoma'. Together they form a unique fingerprint.

Cite this